Afatinib (BIBW2992) in HER2 (Human Epidermal Growth Factor Receptor 2)-Overexpressing Inflammatory Breast Cancer

Clinical trial NCT01325428 · COMPLETED

Trial details

NCT number: NCT01325428
Sponsor: Boehringer Ingelheim
Status: COMPLETED
Phase: Phase 2
Study type: INTERVENTIONAL

Breast Neoplasms

Start date: 2011-08-01
Primary completion: 2014-11-01
Enrollment: 26

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.